LifeSpan BioSciences, Inc. announces the acquisition of Everest Biotech
Release Date: July 31st, 2019
Seattle, Washington State, USA– June 2019 – LifeSpan BioSciences (LSBio), a leading provider of antibodies and life science research reagents is pleased to announce its acquisition of Everest Biotech. Everest Biotech are ISO 9001:2015 certified experts in antigen affinity purified goat polyclonal antibodies.
The acquisition of Everest Biotech further expands the LSBio product offering and strengthens LSBio’s position as one of the fastest growing companies in the research reagent market. LSBio through its partnerships now offers a comprehensive catalogue of reagents that can be coupled with their extensive collection of IHC validated primary antibodies.
“We are looking forward to adding the Everest Biotech product range to the LSBio portfolio” said Heather Holemon, CEO of LSBio. “Everest Biotech’s products are of exceptionally high quality and they complement our existing portfolio perfectly”.
Everest Biotech’s commitment to quality and continuous improvement has ensured that their catalogue has grown, containing thousands of goat antibodies against a broad range of human, mouse and rat targets of biomedical interest. This will broaden LSBio’s current offering of over 500,000 monoclonal and polyclonal primary antibodies to virtually every protein in the proteome. Through extensive ongoing in-house testing, more than 15,000 of the LSBio antibodies have also been identified as exceptional IHC reagents and given the IHC-plus™ brand.
About LifeSpan BioSciences
LifeSpan BioSciences was founded in 1995 by Doctors Joseph Brown and Glenna Burmer and was established as a molecular pathology company with a focus on protein localisation in diseased human tissue by IHC.
In addition to antibodies and IHC reagents, LSBio offers over 50,000 high-quality immunoassays, including sandwich ELISA (enzyme-linked immunosorbent assay) kits, competitive EIA (Enzyme Immunoassay) kits, as well as cell-based and DNA-binding ELISA kits. LSBio also offers a range of recombinant and native proteins and lysates.
This acquisition of Everest Biotech, is the second by LSBio this year, following the successful integration of the Nordic-MUbio/Exalpha Biologicals Companies in February.
LSBio’s services include custom IHC studies supported by a massive archival human tissue bank, and tissue cross-reactivity screening.
For more information, visit https://www.lsbio.com/